Patents by Inventor Francis J. Martin
Francis J. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20010051183Abstract: A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 &mgr;g agent/&mgr;mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.Type: ApplicationFiled: April 26, 2001Publication date: December 13, 2001Applicant: Alza CorporationInventors: Francis J. Martin, Martin C. Woodle, Carl Redemann, Annie Yau-Young
-
Patent number: 6326353Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.Type: GrantFiled: March 23, 1993Date of Patent: December 4, 2001Assignee: Sequus Pharmaceuticals, Inc.Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz
-
Publication number: 20010043929Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.Type: ApplicationFiled: June 8, 2001Publication date: November 22, 2001Applicant: Alza CorporationInventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz, Herve Bercovier
-
Patent number: 6316024Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.Type: GrantFiled: March 2, 2000Date of Patent: November 13, 2001Assignee: Sequus Pharmaceuticals, Inc.Inventors: Theresa M. Allen, Paul Uster, Francis J. Martin, Samuel Zalipsky
-
Publication number: 20010038851Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.Type: ApplicationFiled: June 7, 2001Publication date: November 8, 2001Applicant: Alza CorporationInventors: Theresa M. Allen, Paul Uster, Francis J. Martin, Samuel Zalipsky
-
Patent number: 6224903Abstract: A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a polymer-lipid conjugate for use in promoting fusion between target membranes. The conjugate is composed of a first segment composed of a hydrophilic polymer and a second hydrophobic polymer segment. The second segment is joined to the first segment by a bond effective to release the first segment in response to an existing or an induced physiologic condition. Attached to the second segment is a vesicle-forming lipid member.Type: GrantFiled: December 10, 1998Date of Patent: May 1, 2001Assignee: Sequus Pharmaceuticals, Inc.Inventors: Francis J. Martin, Samuel Zalipsky
-
Patent number: 6180134Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.Type: GrantFiled: June 7, 1995Date of Patent: January 30, 2001Assignee: Sequus Pharmaceuticals, Inc.Inventors: Samuel Zalipsky, Martin C. Woodle, Francis J. Martin, Yechezkel Barenholz
-
Patent number: 6056973Abstract: Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by incubating the liposomal composition with a selected conjugate.Type: GrantFiled: August 21, 1998Date of Patent: May 2, 2000Assignee: Sequus Pharmaceuticals, Inc.Inventors: Theresa M. Allen, Paul Uster, Francis J. Martin, Samuel Zalipsky
-
Patent number: 6043094Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.Type: GrantFiled: October 10, 1997Date of Patent: March 28, 2000Assignee: Sequus Pharmaceuticals, Inc.Inventors: Francis J. Martin, Samuel Zalipsky, Shi Kun Huang
-
Patent number: 5972379Abstract: A liposome composition for treating a bacterial infection is described. The composition includes liposomes having a surface coating of hydrophilic polymer chains and an entrapped drug-conjugate composed of ciprofloxacin conjugated to an amino acid.Type: GrantFiled: April 2, 1998Date of Patent: October 26, 1999Assignee: Sequus Pharmaceuticals, Inc.Inventors: Luke S. S. Guo, Josh Gittelman, Samuel Zalipsky, Francis J. Martin
-
Patent number: 5891468Abstract: A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.Type: GrantFiled: October 10, 1997Date of Patent: April 6, 1999Assignee: SEQUUS Pharmaceuticals, Inc.Inventors: Francis J. Martin, Samuel Zalipsky
-
Patent number: 5843473Abstract: A method of treating a site of systemic infection which includes administering a therapeutic compound entrapped in liposomes. Also included is a liposomal composition and a method of preparing a liposomal composition for use in concentrating a therapeutic compound to an infected region via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids, a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.2 microns. After parenteral administration, the liposomes are selectively taken up by the infected region within 24-48 hours, for release of entrapped compound into the infected region.Type: GrantFiled: March 27, 1992Date of Patent: December 1, 1998Assignee: SEQUUS Pharmaceuticals, Inc.Inventors: Martin C. Woodle, Irma A.J.M. Bakker-Woudenberg, Francis J. Martin
-
Patent number: 5631018Abstract: A lipid-polymer conjugate for use in forming long-circulating liposomes is disclosed. The conjugate includes a vesicle-forming lipid having covalently attached to its polar head group, one of the polymers: polyvinylpyrrolidone, polyvinylmethylether, polyhydroxypropyl methacrylate, polyhydroxypropylmethacrylamide, polyhydroxyethyl acrylate, polymethacrylamide, polydimethylacrylamide, polymethyloxazoline, polyethyloxazoline, polyhydroxyethyloxazoline, polyhydroxypropyloxazoline, or polyaspartamide. A method for preparing liposomes containing the lipid-polymer conjugate is also disclosed.Type: GrantFiled: October 4, 1994Date of Patent: May 20, 1997Assignee: Sequus Pharmaceuticals, Inc.Inventors: Samuel Zalipsky, Martin C. Woodle, Danilo D. Lasic, Francis J. Martin
-
Patent number: 5620689Abstract: A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte or T-lymphocyte lineage cells is described. The method includes administering a suspension of liposomes having a surface coating of polyethylene glycol chains. Attached to the distal ends of the chains are antibodies or antibody fragments effective to bind to an antigen specific to the affected cells. In one embodiment, anti-CD19 antibodies are attached to the liposome-bound chains, for treatment of multiple myeloma.Type: GrantFiled: June 7, 1995Date of Patent: April 15, 1997Assignee: Sequus Pharmaceuuticals, Inc.Inventors: Theresa M. Allen, Francis J. Martin
-
Patent number: 5534259Abstract: A composition of polymer-coated particles, and a polymer compound used in forming the particles are disclosed. The polymer compound is composed of a hydrophilic polymer attached to a lipophilic moiety through a linking segment which contains chemical groups through which the compound can be crosslinked to other such compounds. The particles in the composition are prepared by forming lipid structures containing ordered arrays of the polymer compounds, and crosslinking the compounds through their chemical groups. The particles are used for parenteral administration of a pharmaceutical compound which is entrapped in the particles.Type: GrantFiled: July 8, 1993Date of Patent: July 9, 1996Assignee: Liposome Technology, Inc.Inventors: Samuel Zalipsky, Francis J. Martin
-
Patent number: 5527528Abstract: A method of administering an anti-tumor compound to a subject is disclosed. The method includes administering to a subject liposomes having sizes predominantly in the range 0.05 to 0.12 microns, and containing an anti-tumor compound in liposome-entrapped form, a surface coating of polyethylene glycol chains, at a surface concentration thereof sufficient to extend the blood circulation time of the liposomes severalfold over that of liposomes in the absence of such coating, and surface-attached antibody molecules effective to bind specifically to tumor-associated antigens present at the tumor site. One liposome composition includes doxorubicin in entrapped form, and, on the liposome surface, a monoclonal antibody against highly proliferating cells in a lung squamous cell carcinoma.Type: GrantFiled: March 31, 1993Date of Patent: June 18, 1996Assignee: Sequus Pharmaceuticals, Inc.Inventors: Theresa M. Allen, Francis J. Martin
-
Patent number: 5395619Abstract: A lipid-polymer conjugate for use in forming long-circulating liposomes is disclosed. The conjugate includes a vesicle-forming lipid having covalently attached to its polar head group, one of the polymers: polyvinylpyrrolidone, polyvinylmethylether, polyhydroxypropyl methacrylate, polyhydroxypropylmethacrylamide, polyhydroxyethyl acrylate, polymethacrylamide, polydimethylacrylamide, polymethyloxazoline, polyethyloxazoline, polyhydroxyethyloxazoline, polyhydroxypropyloxazoline, or polyaspartamide. A method for preparing liposomes containing the lipid-polymer conjugate is also disclosed.Type: GrantFiled: March 3, 1993Date of Patent: March 7, 1995Assignee: Liposome Technology, Inc.Inventors: Samuel Zalipsky, Martin C. Woodle, Danilo D. Lasic, Francis J. Martin
-
Patent number: 5356633Abstract: A method of and composition for concentrating a therapeutic agent in an inflamed dermal region are disclosed. The composition, which is also used in the method, is a liposomal composition. The liposomes contain the therapeutic agent in entrapped form and are composed of vesicle-forming lipids including a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer. After intravenous administration, the liposomes are taken up by the inflamed region within 24-48 hours, for site-specific release of entrapped compound into the inflamed region.Type: GrantFiled: October 7, 1992Date of Patent: October 18, 1994Assignee: Liposome Technology, Inc.Inventors: Martin C. Woodle, Francis J. Martin, Shi K. Huang
-
Patent number: 5225212Abstract: A liposome composition for extended release of a therapeutic compound into the bloodstream. The liposomes are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic polymer, have sizes in a selected size range between 0.1 and 0.4 microns, and contain the therapeutic compound in liposome-entrapped form. The dosage form of the composition contains at least about three times the dose of the compound required for intravenous injection in free form. Also disclosed in a method for extending to at least 24 hours the period in which an intravenously administered therapeutic compound is therapeutically active in the bloodstream, and novel liposomes compositions for practicing the method.Type: GrantFiled: December 10, 1990Date of Patent: July 6, 1993Assignee: Liposome Technology, Inc.Inventors: Francis J. Martin, Martin C. Woodle, Carl Redemann, Annie Yau-Young, Ramachandran Radhakrishnan
-
Patent number: 5213804Abstract: A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 .mu.g agent/.mu.mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.Type: GrantFiled: January 15, 1991Date of Patent: May 25, 1993Assignee: Liposome Technology, Inc.Inventors: Francis J. Martin, Martin C. Woodle, Carl Redemann, Annie Yau-Young